The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Subscribe To Our Newsletter & Stay Updated
